Phase 1 Macular Degeneration Clinical Trials
21 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 21 trials
Recruiting
Phase 1Phase 2
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular Degeneration
AbbVie66 enrolled4 locationsNCT07160179
Recruiting
Phase 1Phase 2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Geographic AtrophyDry Age-Related Macular Degeneration
National Eye Institute (NEI)20 enrolled2 locationsNCT04339764
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775
Recruiting
Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-Related Macular Degeneration
Astellas Institute for Regenerative Medicine42 enrolled19 locationsNCT03178149
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667
Recruiting
Phase 1Phase 2
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD
Perceive Biotherapeutics, Inc.60 enrolled11 locationsNCT06087458
Recruiting
Phase 1
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872
Recruiting
Phase 1
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Age-Related Macular Degeneration
Benobio Co., Ltd.18 enrolled2 locationsNCT05803785
Recruiting
Phase 1Phase 2
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Stargardt DiseaseStargardt Macular DystrophyStargardt Macular Degeneration
Splice Bio57 enrolled5 locationsNCT06942572
Recruiting
Phase 1
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Retinitis PigmentosaMacular DegenerationDiabetic Retinopathy+3 more
The Foundation for Orthopaedics and Regenerative Medicine20 enrolled2 locationsNCT05147701
Recruiting
Phase 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Age-related Wet Macular Degeneration
Caregen Co. Ltd.45 enrolled7 locationsNCT06132035
Recruiting
Phase 1Phase 2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.68 enrolled9 locationsNCT05986864
Recruiting
Phase 1
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Youxin Chen12 enrolled3 locationsNCT06213038
Recruiting
Phase 1Phase 2
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Age-Related Macular Degeneration
Chengdu Origen Biotechnology Co., Ltd.42 enrolled1 locationNCT05672121
Recruiting
Phase 1Phase 2
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Shanghai Refreshgene Technology Co., Ltd.48 enrolled1 locationNCT06141460
Recruiting
Phase 1Phase 2
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232
Recruiting
Phase 1Phase 2
Gene Therapy(FT-003) for Wet AMD
Neovascular Age-related Macular Degeneration
Frontera Therapeutics78 enrolled1 locationNCT06492863
Completed
Phase 1
A Phase 1b, Open-Label, Parallel Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Tinlarebant in Healthy Volunteers Aged 50-85
Dry Age related macular degeneration (AMD)
RBP4 Pty Ltd16 enrolled1 locationACTRN12622001520729
Recruiting
Phase 1
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
Macular Degeneration
Beijing Tongren Hospital10 enrolled1 locationNCT05445063
Completed
Phase 1
A study to determine the safety and tolerability of an intravitreal steroid in the treatment of dry Age Related Macular Degeneration.
Geographic Atrophy secondary to Age Related Macular Degeneration
Eye Co Pty Ltd10 enrolled1 locationACTRN12618001308280